A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 118, Issue 6, Pages 793-801
Publisher
Springer Nature
Online
2018-02-14
DOI
10.1038/bjc.2017.495
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
- (2016) Shubham Pant et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia
- (2015) Ivan Diaz-Padilla et al. GYNECOLOGIC ONCOLOGY
- Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors
- (2015) Ashvinikumar V. Gavai et al. ACS Medicinal Chemistry Letters
- Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933
- (2014) Sylvia M. Lee et al. CANCER
- A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral -Secretase Inhibitor PF-03084014
- (2014) W. A. Messersmith et al. CLINICAL CANCER RESEARCH
- A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
- (2014) Ana De Jesus-Acosta et al. INVESTIGATIONAL NEW DRUGS
- Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer
- (2013) Shinichi Yabuuchi et al. CANCER LETTERS
- Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression
- (2013) Vindhya Palagani et al. CARCINOGENESIS
- A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
- (2013) Ivan Diaz-Padilla et al. INVESTIGATIONAL NEW DRUGS
- A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
- (2013) Suzanne Richter et al. INVESTIGATIONAL NEW DRUGS
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of RO4929097 in metastatic colorectal cancer
- (2012) Jonathan R. Strosberg et al. EUROPEAN JOURNAL OF CANCER
- Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
- (2012) Ian Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
- (2012) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma
- (2012) Natalie Cook et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer
- (2012) John Whitehead et al. STATISTICS IN MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological Analysis of Drosophila melanogaster -Secretase with Respect to Differential Proteolysis of Notch and APP
- (2010) C. Groth et al. MOLECULAR PHARMACOLOGY
- The Notch signaling pathway: Transcriptional regulation at Notch target genes
- (2009) T. Borggrefe et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer
- (2009) M. E. Mullendore et al. CLINICAL CANCER RESEARCH
- Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma
- (2009) Ruben Plentz et al. GASTROENTEROLOGY
- Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway
- (2009) Jun Yao et al. MEDICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started